Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck KGaA Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of 20.7 billion to 22.1 billion euros.
Merck KGaA Q3 earnings rise faster than expected on lower costs
FRANKFURT, Nov 14 (Reuters) -
Merck
KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug development and a rebound in demand for its specialty materials. The German ...
Growth brings higher profits at Germany's Merck
Driven by growth across the board, including in its semiconductor business, German science and technology company Merck reported profit after tax of €812 million ($857 million) or €1.86 per share for the third quarter.
Merck KGaA Earnings Growth Beats Expectations
Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in life-sciences, but cautioned that full-year sales would come in at the bottom end of the forecast range.
FiercePharma
20h
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Yale Daily News
8h
Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal
On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with
Merck
, an American pharmaceutical ...
6d
Merck: An Undervalued Dividend Machine
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
pharmaphorum
1d
Merck drug for rare tumour hits phase 3 target
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
FierceBiotech
2d
Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono
Merck
KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...
bnnbloomberg
3h
Merck KGaA Beats Estimates on Boost From Life Science Unit
(Bloomberg) --
Merck
KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...
The Motley Fool on MSN
12d
Is Merck Stock a Buy?
Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then
Merck
will face biosimilar ...
2h
Merck Foundation Marking "World Diabetes Day" by Providing out of 2080 Scholarships, 830 Scholarships for Diabetes and Hypertension in 52 Countries
Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ’World Diabetes Day 2024’ together with Africa’s First Ladies, Ministries of Health, Medical Societies and Academia, through their ...
Daily
4h
Ginkgo Bioworks advances collaboration with Merck to improve Biologics manufacturing
Boston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ginkgo Bioworks
Net income
Feedback